PMID- 22268394
OWN - NLM
STAT- MEDLINE
DCOM- 20120718
LR  - 20211021
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Print)
IS  - 1573-3998 (Linking)
VI  - 8
IP  - 2
DP  - 2012 Mar
TI  - Testosterone as potential effective therapy in treatment of obesity in men with 
      testosterone deficiency: a review.
PG  - 131-43
AB  - OBJECTIVE: Obesity negatively affects human health. Limiting food intake, while 
      producing some weight loss, results in reduction of lean body mass. Combined with 
      moderate exercise it produces significant weight loss, maintains lean body mass 
      and improves insulin sensitivity, but appears difficult to adhere to. Bariatric 
      surgery is clinically effective for severely obese individuals compared with 
      non-surgical interventions, but has limitations. Clinical and pre-clinical 
      studies have implicated a role for testosterone (T) in the patho-physiology of 
      obesity. EVIDENCE ACQUISITION AND SYNTHESIS: A literature search in PubMed on the 
      role of T in counteracting obesity and its complications. RESULTS: Obesity per se 
      impairs testicular T biosynthesis. Furthermore, lower-than-normal T levels 
      increase accumulation of fat depots, particularly abdominal (visceral) fat. This 
      fat distribution is associated with development of metabolic syndrome (MetS) and 
      its sequels, namely type 2 diabetes mellitus (T2DM) and cardiovascular disease 
      (CVD). T treatment reverses fat accumulation with significant improvement in lean 
      body mass, insulin sensitivity and biochemical profiles of cardiovascular risk. 
      The contribution of T to combating obesity in hypogonadal men remains largely 
      unknown to medical professionals managing patients with obesity and metabolic 
      syndrome. Many physicians associate T treatment in men with risks for prostate 
      malignancy and CVD. These beliefs are not supported by recent insights. 
      CONCLUSION: While overall treatment of obesity is unsuccessful, T treatment of 
      hypogonadal men may be effective, also because it improves mood, energy, reduces 
      fatigue and may motivate men to adhere to diet and exercise regimens designed to 
      combat obesity.
CI  - (c) 2012 Bentham Science Publishers
FAU - Saad, Farid
AU  - Saad F
AD  - Bayer Pharma, Scientific Affairs Men's Healthcare, Berlin, Germany. 
      Farid.Saad@bayer.com
FAU - Aversa, Antonio
AU  - Aversa A
FAU - Isidori, Andrea M
AU  - Isidori AM
FAU - Gooren, Louis J
AU  - Gooren LJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Diabetes Mellitus, Type 2/etiology/prevention & control
MH  - Diet, Reducing
MH  - Exercise
MH  - Humans
MH  - Hypogonadism/*drug therapy/metabolism
MH  - Intra-Abdominal Fat/metabolism
MH  - Male
MH  - Metabolic Syndrome/etiology/prevention & control
MH  - Obesity/complications/*drug therapy/metabolism
MH  - Patient Compliance
MH  - Risk Reduction Behavior
MH  - Testosterone/biosynthesis/*deficiency/*therapeutic use
PMC - PMC3296126
EDAT- 2012/01/25 06:00
MHDA- 2012/07/19 06:00
CRDT- 2012/01/25 06:00
PHST- 2011/10/28 00:00 [received]
PHST- 2011/11/28 00:00 [revised]
PHST- 2011/12/22 00:00 [accepted]
PHST- 2012/01/25 06:00 [entrez]
PHST- 2012/01/25 06:00 [pubmed]
PHST- 2012/07/19 06:00 [medline]
AID - EPUB-CDR-20120123-001 [pii]
AID - CDR-8-131 [pii]
AID - 10.2174/157339912799424573 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2012 Mar;8(2):131-43. doi: 10.2174/157339912799424573.